Capsaicin 8% Patch Repeat Treatment in Non-diabetic Peripheral Neuropathic Pain: A 52-week, Open-label, Single-arm, Safety Study.

In Study 10 (NCT01482715), ARIEL2 (NCT01891344) and ARIEL4 (NCT02855944) [6, 8, 9], rucaparib demon- strated improved PFS in the treatment setting in patients with

The study showed that patients were satisfied with the received treatment, even when they were in pain, and that patient dissatisfaction was related to the pain intensity

Conclusions: Our experience suggests that 1000 mg rituximab single in- fusion on demand is a reasonable schedule for long-term treatment of those patients with good response after

In animals, nicotine and other nAChRs agonists induce antinociceptive effects in several models of acute, inflammatory and neuropathic pain (Berrendero et al. 2005; Flores

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY):

The specific objectives of the present study are: (1) to examine whether there are differences in perceived joint pain between weather-sensitive and non-weather- sensitive people

Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study..

Here, we report 52-week treatment results from the OC5-DB-02 study, a Phase III, randomized, double-blind study evaluating the efficacy and safety of Oxabact versus placebo